Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuing Sodium Zirconium Cyclosilicate After Hospital Discharge in CKD Patients Treated for Hyperkalemia
2021-003527-14Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hyperkalemia comparing SZC continuation plus standard of care with Standard of care alone (2 arms). Primary endpoint: Occurrence of normokalemia at 180 days post-discharge. Started Sep 2021; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2021-003527-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003527-14.